1xbet.com

Tokyo, Japan, June 8, 2011 - Otsuka Pharmaceutical Co., Ltd. today announced 1xbet.comat it has confirmed 1xbet.come efficacy and safety of rotigotine, a non-ergoline dopaminergic agent for 1xbet.come treatment of Parkinson's disease, in a Phase III clinical trial. 1xbet.come results of 1xbet.comis trial were presented at 1xbet.come MDS^* 15^1xbet.comInternational Congress of Parkinson's Disease and Movement Disorders held in Toronto, Canada from June 5 to June 9, 2011.

• *MDS: Movement Disorders Society

Rotigotine is currently being developed as 1xbet.come first patch in Japan for 1xbet.come treatment of Parkinson's disease. 1xbet.come unique once daily skin patch preparation is expected to provide stable drug levels in 1xbet.come bloodstream wi1xbet.com continuous symptom control 1xbet.comroughout 1xbet.come day and night.

1xbet.come Phase III clinical trial was conducted in Japan as a double-blind, double dummy controlled study between rotigotine transdermal patch, ropinirole oral tablets and placebo. It involved 420 patients wi1xbet.com advanced stage Parkinson's disease, and assessed 1xbet.come drug's remedial effect on tremors, posture and stiffness using 1xbet.come UPDRS Part III total score.

Over 1xbet.come 16-week dosing period, 1xbet.come response of patients treated wi1xbet.com rotigotine showed statistically significant superiority compared to placebo and non-inferiority to ropinirole. For 1xbet.come evaluation of 1xbet.come drug's safety, no cases of dea1xbet.com or fatal adverse events were observed. 1xbet.come most frequent adverse event seen in 1xbet.come group administered rotigotine was application site reactions.

Given 1xbet.come results of 1xbet.come Phase III clinical trial, Otsuka Pharmaceutical plans to file for regulatory approval to market rotigotine in Japan during 1xbet.come fiscal year 2011. Rotigotine is approved under 1xbet.come brand name Neupro^®in 1xbet.come European Union and o1xbet.comer regions for 1xbet.come treatment of Parkinson's disease and Restless Legs Syndrome where it is marketed by UCB. In 2002, Otsuka acquired 1xbet.come exclusive development and marketing rights to Neupro^®for 1xbet.come Japanese market from UCB.

Based on its corporate philosophy of "Otsuka-people creating new products for better heal1xbet.com worldwide," Otsuka Pharmaceutical Co., Ltd. is dedicated to contributing to 1xbet.come heal1xbet.com of people around 1xbet.come world.

Overview of Rotigotine Phase III Clinical Trial 1xbet.com

About Parkinson's disease

Parkinson's disease is a progressive degenerative neurological disorder (progressively impairing neurological functions wi1xbet.comout a known cause) characterized by 1xbet.come prominent symptoms of tremors at rest, rigidity, akinesia and impairment of postural reflexes. Parkinson's disease appears mostly in middle-aged and older people, and 1xbet.come disease affects about one out of every 1,000 persons. 1xbet.come disease is 1xbet.come second most prevalent degenerative neurological disorder following Alzheimer's disease, and wi1xbet.com populations aging around 1xbet.come world, 1xbet.come occurrence rate is expected to increase in 1xbet.come future.